DEPARTMENT OF HUMAN SERVICES

Meeting Minutes: Drug Formulary Committee - DRAFT

Date and Time:	March 22, 2023; 5:15 – 9:00 p.m.
Minutes prepared by:	Naana Osei-Boateng and Dave Hoang
Location:	Virtual Meeting via Zoom or In-person Meeting at Elmer Andersen Building, Room 2370

Attendance

- Members in attendance: Stuart Williams, JD; Kelly Ruby, PharmD; Kathryn Lombardo, MD; Margaret Artz, RPh, PhD; Tim Cernohous, PharmD; Ronda Chakolis, PharmD; Mary Mescher Benbenek, APRN, PhD.
- Members absent: Tsewang Ngodup, MD; Kyle Lehenbauer, MD; Monica Brands, RPh; Kathryn Montag-Shafer, PharmD; James Phillips, MD; Michael Sprehe, MD
- DHS staff present: Dave Hoang, PharmD, MBA; Chad Hope, PhamD; Nathan Chomilo, MD
- Others in attendance: Katie Counts, PharmD; Umang Patel, PharmD; Naana Osei-Boateng, PharmD

Report of the Chair

- Stuart Williams presided over the meeting.

Approval of Minutes

- The committee reviewed and accepted the Minutes from the November 2022 meeting as presented.

DHS Housekeeping

- The Drug Formulary Committee (DFC) chair reminded members and presenters who wish to provide live testimony at DFC meetings were reminded to complete their conflict-of-Interest disclosure forms

Old Business – The Minnesota Department of Human Services (DHS) shared that DHS reviewed comments received from the public and committee members regarding possible changes to the format of the DFC meeting. After careful consideration and due to a lack of consensus, DHS decided to make only one change to the DFC meeting format; and that is to shorten the meeting by 30 minutes with the goal of ending the meeting by 8:30 p.m.

New Business – None

Preferred Drug List (PDL) Review

- The committee discussed the Stimulants and Related Agents therapeutic class and recommended the following to the department by a unanimous vote:
    - AMPHETAMINE SALT COMBO ER (ORAL) and METHYLPHENIDATE ER (CONCERTA) (ORAL) to be added to the PDL as PREFERRED
    - METHYLPHENIDATE PATCH (DAYTRANA) (TRANSDERMAL) and XELSTRYM (TRANSDERMAL) to be added to the PDL as NONPREFERRED
    - ADZENYS ER SUSPENSION (ORAL) to be removed from the PDL.

Specialty Drugs for Continued Prior Authorization (PA)

- The DFC unanimously voted to recommend to DHS to revise the Consent Agenda Item Policy to consider proposed prior authorization (PA) criteria sheets, that are drafted according to FDA-approved label, to be consent agenda items; and to allow DFC voting member the opportunity to request that any proposed PA criteria sheet considered consent agenda item be moved to the full agenda for discussion.

- The committee discussed Imcivree and recommended to the Department of Human Services (DHS) by a unanimous vote that Imcivree remain on PA with the proposed criteria.

- The committee discussed Cibinqo and recommended to DHS by a unanimous vote that Cibinqo remain on PA with the proposed criteria.

- The committee discussed Camzyos and recommended to DHS by a unanimous vote that Camzyos remain on PA with the proposed criteria.

- The committee discussed Amvuttra and recommended to DHS by a unanimous vote that Amvuttra remain on PA with the proposed criteria.

- The committee discussed Vivjoa and recommended to DHS by a unanimous vote that Vivjoa remain on PA with the proposed criteria, with the following change:
    - Amend the 6th bullet point under approval criteria to read: Patient has tried and failed or has a contraindication or intolerance to maintenance antifungal therapy with **weekly** oral fluconazole for 6 months.

- The committee discussed Zoryve and recommended to DHS by a unanimous vote that Zoryve remain on PA with the proposed criteria.

- The committee discussed Ztalmy and recommended to DHS by a unanimous vote that Ztalmy remain on PA with the proposed criteria, with the following changes:

- The committee discussed Spevigo and recommended to DHS by a unanimous vote that Spevigo remain on PA with the proposed criteria.

- The committee discussed Xenpozyme and recommended to DHS by a unanimous vote that Xenpozyme remain on PA with the proposed criteria.

- The committee discussed Lytgobi and recommended to DHS by a unanimous vote that Lytgobi remain on PA with the proposed criteria.

- The committee discussed Imjudo and recommended to DHS by a unanimous vote that Imjudo remain on PA with the proposed criteria, with the following changes.
- The committee discussed Scenesse and recommended to DHS by a unanimous vote that Scenesse remain on PA with the proposed criteria.

- The committee discussed Relyvrio and recommended to DHS by a unanimous vote that Relyvrio remain on PA with the proposed criteria.

- The committee discussed Hemgenix and recommended to DHS by a unanimous vote that Hemgenix remain on PA with the proposed criteria.

- The committee discussed Rezlidhia i and recommended to DHS by a unanimous vote that Rezlidhia remain on PA with the proposed criteria.

- The committee discussed Elahere and recommended to DHS by a unanimous vote that Elahere remain on PA with the proposed criteria.

Drugs for Continued PA

- The committee discussed Verkazia and recommended to DHS by a unanimous vote that Verkazia remain on PA with the proposed criteria.

Existing Specialty Drugs for Continued Prior Authorization (PA) – Dave

Consent Agenda Item:

- The committee discussed Sublocade under the Consent Agenda Policy and recommended to the department by a unanimous vote that Sublocade remain on PA with the proposed updated criteria.

Adjournment

- The meeting was adjourned at approximately 8:10 p.m. Central Time.